A new report highlights the potential risk in concomitant use of the anticoagulant dabigatran, and phenytoin, a P-glycoprotein (P-gp) inducer used to treat seizure disorders.
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation
Boehringer Ingelheim announced results demonstrating that its investigational fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran in healthy male volunteers.
At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation resulted in no major post-procedural complications.